Table S1: Demographic information and treatment information for each child with psoriasis

| Patient | Type  | Gender | Age | Age of Onset | Baseline PASI | Previous Treatment         | Start Treatment of the Study | Adverse Events | Switching of Biologies | Reached 52 Weeks |
|---------|-------|--------|-----|--------------|---------------|----------------------------|-----------------------------|----------------|------------------------|------------------|
| 1       | Plaque | F      | 17  | 11           | 15            | Adalimumab                | No                          | Yes            | Switched to Secukinumab at week 28 | No               |
| 2       | Plaque | M      | 16  | 13           | 9.8           | Adalimumab                | No                          | Yes            |                        |                  |
| 3       | Plaque | F      | 10  | 7            | 12.6          | Adalimumab                | No                          | Yes            |                        |                  |
| 4       | Plaque | M      | 15  | 12           | 3.2           | Acitretin, Etanercept     | Adalimumab                | No                          | Switched to Secukinumab at week 64 | Yes            |
| 5       | Plaque | M      | 13  | 8            | 15.9          | Adalimumab                | Upper respiratory infection | No                          |                        | Yes            |
| 6       | Plaque | F      | 14  | 13           | 2.7           | Tripterygium wilfordii    | Adalimumab                | No                          | Switched to Secukinumab at week 64 | Yes            |
| 7       | Plaque | M      | 12  | 9            | 15            | Methotrexate, Etanercept  | Adalimumab                | No                          |                        | Yes            |
| 8       | Plaque | M      | 17  | 17           | 12            | Adalimumab                | No                          | Yes            |                        |                  |
| 9       | Plaque | F      | 6   | 4            | 11.1          | Adalimumab                | No                          | Yes            |                        |                  |
| 10      | Plaque | F      | 10  | 9            | 22            | Adalimumab                | No                          | Yes            |                        |                  |
| 11      | Plaque | M      | 17  | 15           | 7.4           | Adalimumab                | No                          | No                          |                        | No              |
| 12      | Nail   | M      | 9   | 7            | 48 (NAPSI)    | Adalimumab                | Upper respiratory infection | Switched to Secukinumab at week 24 | Yes            |
| 13      | Plaque | F      | 7   | 4            | 22.4          | Adalimumab                | Secukinumab                | No                          | Yes            |
| 14      | Plaque | M      | 17  | 13           | 18.6          | Secukinumab                | No                          | Yes            |                        |                  |
| 15      | Plaque | M      | 16  | 13           | 24.8          | Secukinumab                | Upper respiratory infection, skin fungal infection | Yes            |
| 16      | Plaque | M      | 15  | 9            | 35            | Secukinumab                | No                          | Yes            |                        |                  |
| 17      | Plaque | M      | 17  | 3            | 12            | Secukinumab                | No                          | No                          |                  |
| No. | Condition   | Gender | Age | Body Temperature | Treatment | Previous Treatment | Response |
|-----|-------------|--------|-----|------------------|-----------|--------------------|----------|
| 18  | Plaque      | M      | 17  | 8                | Secukinumab | No                 | Yes      |
| 19  | Plaque      | F      | 9   | 5                | Secukinumab | No                 | Yes      |
| 20  | Plaque      | M      | 16  | 13               | Secukinumab | No                 | Yes      |
| 21  | Plaque      | F      | 8   | 6                | Secukinumab | No                 | Yes      |
| 22  | Plaque      | M      | 8   | 7                | Secukinumab | No                 | No       |
| 23  | Plaque      | F      | 8   | 5                | Secukinumab | No                 | No       |
| 24  | Plaque      | F      | 13  | 3                | Secukinumab | No                 | No       |
| 25  | Plaque      | F      | 10  | 10               | Secukinumab | No                 | No       |
| 26  | Plaque      | M      | 17  | 5                | Secukinumab | No                 | No       |
| 27  | Plaque      | F      | 5   | 5                | Secukinumab | No                 | No       |
| 28  | Plaque      | M      | 13  | 5                | Secukinumab | No                 | No       |
| 29  | Plaque      | F      | 16  | 12               | Secukinumab | Cutaneous pruritus | No       |
| 30  | Plaque      | F      | 17  | 15               | Secukinumab | No                 | No       |
| 31  | Plaque      | M      | 13  | 7                | Acitretin   | Secukinumab        | No       |
| 32  | Plaque      | F      | 11  | 8                | Secukinumab | No                 | No       |
| 33  | Plaque      | F      | 7   | 5                | Secukinumab | No                 | No       |
| 34  | Plaque      | F      | 3   | 2                | Secukinumab | No                 | No       |
| 35  | Plaque      | F      | 17  | 15               | Acitretin, Adalimumab | Ixekizumab | No     | Yes     |
| 36  | Pustular    | M      | 11  | 8                | Ixekizumab  | No                 | Yes      |
| 37  | Plaque      | M      | 14  | 4                | Acitretin   | Ixekizumab         | No       | Yes     |
| 38  | Plaque      | M      | 17  | 11               | Ixekizumab  | No                 | No       |